Maxim Group set a $6.00 target price on Cancer Genetics (NASDAQ:CGIX) in a research note issued to investors on Wednesday. The firm currently has a buy rating on the medical research company’s stock.

Several other analysts have also recently issued reports on the company. ValuEngine cut Cancer Genetics from a hold rating to a sell rating in a research report on Friday, September 1st. HC Wainwright reiterated a buy rating and set a $6.00 target price on shares of Cancer Genetics in a research report on Thursday, September 21st. Finally, Zacks Investment Research cut Cancer Genetics from a hold rating to a sell rating in a research report on Wednesday, October 4th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of $5.56.

Cancer Genetics (NASDAQ:CGIX) traded up $0.10 during trading hours on Wednesday, hitting $1.95. The company had a trading volume of 366,300 shares, compared to its average volume of 256,179. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.01 and a quick ratio of 2.01. Cancer Genetics has a 12-month low of $1.30 and a 12-month high of $5.30.

In other Cancer Genetics news, Director John Pappajohn bought 150,000 shares of the business’s stock in a transaction that occurred on Friday, December 8th. The stock was purchased at an average price of $1.86 per share, for a total transaction of $279,000.00. Following the completion of the transaction, the director now owns 2,781,204 shares of the company’s stock, valued at approximately $5,173,039.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 21.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Cancer Genetics by 61.9% during the 2nd quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock valued at $2,041,000 after buying an additional 197,619 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Cancer Genetics by 44.8% during the 1st quarter. Renaissance Technologies LLC now owns 449,600 shares of the medical research company’s stock valued at $1,843,000 after buying an additional 139,200 shares in the last quarter. Granahan Investment Management Inc. MA grew its holdings in Cancer Genetics by 26.3% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock valued at $641,000 after buying an additional 49,371 shares in the last quarter. Thompson Davis & CO. Inc. grew its holdings in Cancer Genetics by 5,465.0% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock valued at $440,000 after buying an additional 109,300 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in Cancer Genetics by 61.0% during the 2nd quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock valued at $127,000 after buying an additional 12,168 shares in the last quarter. Institutional investors and hedge funds own 12.71% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Cancer Genetics (CGIX) Given a $6.00 Price Target at Maxim Group” was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/12/14/cancer-genetics-cgix-given-a-6-00-price-target-at-maxim-group.html.

About Cancer Genetics

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.